North America Menstrual Cramps Treatment Market, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End User (Hospitals, Specialty Centers, Ambulatory Surgical Centers, Others), Distribution Channel (Pharmacies, Retail Sales, Direct Tender, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028
Market Analysis and Insights : North America Menstrual Cramps Treatment Market
The menstrual cramps treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.6% in the forecast period of 2021 to 2028 and is expected to reach USD 3,335.97 million by 2028. Rising prevalence of menstrual health diseases such as menstrual cramps and extensive research & development activity in menstrual cramps treatment are the major drivers which propelled the demand of the market in the forecast period.
Menstrual cramps are the cramping and throbbing pain in the lower abdomen of the body. Many women have menstrual cramps before and after the menstrual periods. For some women menstrual cramps are common while for other women menstrual cramps are annoying and quite severe which interfere in daily activities for few days of every month. Symptoms of menstrual cramps are pain that starts 1 to 3 days before the period, peaks 24 hours after the onset of the period and subsides in 2 to 3 days along with dullness, continuous ache, nausea, headache, dizziness, loose stools and others.
Menstrual cramps treatment comprises features such as increasing need for effective treatment for menstrual cramps will impact in launching of new product by the manufacturers into the market which enhances its demand as well as rising government & pharmaceutical industries initiatives leads to the menstrual cramps treatment market growth. The use of alternative therapies acts as a challenge for the growth of the menstrual cramps treatment market.
Currently, awareness programmes are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative technology. Moreover, these awareness programmes are also expected to provide various other opportunities in the menstrual cramps treatment market. However, presence of traditional therapies is expected to restraint the menstrual cramps treatment market growth in the forecast period.
The menstrual cramps treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the menstrual cramps treatment market scenario contact Data ridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Menstrual Cramps Treatment Market Scope and Market Size
The menstrual cramps treatment market is segmented on the basis of the type, treatment type, mode of prescription, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. In 2021, primary dysmenorrhea segment is dominating the menstrual cramps treatment market as 85% women in the United States of America suffering from or faces menstrual cramps during their periods.
- On the basis of treatment type, the menstrual cramps treatment market is segmented into medication, therapy, surgery and others. In 2021, medication segment is dominating the menstrual cramps treatment market due to medication nonsteroidal anti-inflammatory drugs and combined oral contraceptives represent first-line therapy for dysmenorrhea pain.
- On the basis of mode of prescription, the menstrual cramps treatment market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating the menstrual cramps treatment market due to most of the drugs are available generic and supply of pharmaceutical products without any hindrance and raising awareness among the masses by the virtues of advertising.
- On the basis of route of administration, the menstrual cramps treatment market is segmented into oral, parenteral, implants and others. In 2021, oral segment is dominating the menstrual cramps treatment market due to oral segment is considered to be the first line of treatment. Furthermore, oral medication has better patient compliance which serves as another driving factor.
- On the basis of end user, the menstrual cramps treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers and others. In 2021, hospitals segment is dominating the menstrual cramps treatment market because most patients are experiencing menopausal symptoms so they would be seen in the hospital to get proper diagnosis and treatment.
- On the basis of distribution channel, the menstrual cramps treatment market is segmented into direct tender, retail sales, pharmacies and others. In 2021, pharmacies segment is dominating the menstrual cramps treatment market as variety of medicines available in the pharmacies according to the patient need and demand.
Menstrual Cramps Treatment Market Country Level Analysis
The menstrual cramps treatment market is analysed and market size information is provided by the country, type, treatment type, mode of prescription, route of administration, end user and distribution channel as referenced above.
The countries covered in the North America menstrual cramps treatment market report are the U.S., Canada, and Mexico.
Mode of prescription segment in North America is expected to dominate the market due to the high adoption of OTC menstrual cramps treatment by the patients in the region. The U.S is dominating in the market and leading the growth in the North America due to increased presence of key market players in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Number of Treatment Options in Menstrual Cramps Treatment Market is Creating New Opportunities for Players in the Market
Menstrual cramps treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with menstrual cramps treatment sales, impact of advancement in the menstrual cramps treatment and changes in regulatory scenarios with their support for the menstrual cramps treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Menstrual Cramps Treatment Market Share Analysis
Menstrual cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to menstrual cramps treatment market.
The major companies which are dealing in the menstrual cramps treatment are Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Beurer GmbH, Mylan N. V. (a part of Viatris Inc.), Boehringer Ingelheim International GmbH, PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation, Alvogen, Cumberland Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc. (a subsidiary of LUPIN), Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd. among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the menstrual cramps treatment market.
For instance,
- In May 2019, PMS4PMS, LLC announces the launch of product named Comforte. The product provides period cramps relief during the menstrual cycle. This new product launched by the company has increased its demand and sales in the market.
Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the menstrual cramps treatment market which also provides the benefit for organisation to improve their offering for menstrual cramps treatment.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
4.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS
5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS
6 PREMIUM INSIGHTS
6.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE
6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS
6.2 MARKETING EXPENSES
6.3 PAYERS:
6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:
7 EPIDEMIOLOGY
8 COVID-19 IMPACT ON NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING PREVALENCE OF DYSMENORRHEA
9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS
9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES
9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE
9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS
9.2 RESTRAINTS
9.2.1 PRODUCT RECALLS
9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN
9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY
9.3 OPPORTUNITIES
9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 RISING DISPOSABLE INCOME
9.4 CHALLENGES
9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT
9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT
9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES
10 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY DYSMENORRHEA
10.3 SECONDARY DYSMENORRHEA
11 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 FIRST LINE TREATMENT
11.2.1.1 Nonhormonal Therapy
11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs
11.2.1.1.1.1 Ibuprofen
11.2.1.1.1.2 Naproxen
11.2.1.1.1.3 Celecoxib
11.2.1.1.1.4 Mefenamic Acid
11.2.1.1.1.5 Meclofenamate
11.2.1.1.2 Acetaminophen
11.2.1.2 Hormonal Replacement Therapy y
11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)
11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol
11.2.1.2.1.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol
11.2.1.2.2.2 Others
11.2.1.2.3 Other
11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol
11.2.1.2.3.2 Etonogestrel Implant
11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System
11.2.1.2.3.4 Medroxyprogesterone Shot
11.2.1.3 Diuretic
11.2.1.3.1 Spironolactone
11.2.1.3.2 Ammonium Chloride
11.2.1.4 Antidepressants
11.2.2 SECOND LINE TREATMENT
11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy
11.2.2.2 Ammonium Chloride
11.3 THERAPY
11.3.1 HEAT THERAPY
11.3.1.1 Patch
11.3.1.2 Wrap
11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)
11.3.2 BEHAVIORAL COUNSELING
11.3.2.1 Desensitization-Based Procedures
11.3.2.2 Coping Strategies
11.3.2.3 Imagery
11.3.2.4 Hypnotherapy
11.3.2.5 Others
11.3.3 DIET AND VITAMINS
11.3.3.1 Vitamin E
11.3.3.2 Vitamin B
11.3.3.3 Vitamin D
11.3.3.4 Others
11.4 SURGERY
11.4.1 ENDOMETRIAL ABLATION
11.4.2 HYSTERECTOMY
11.5 OTHERS
12 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLETS
13.2.2 PILLS
13.2.3 CAPSULE
13.2.4 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 IMPLANTS
13.5 OTHERS
14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CENTERS
14.4 AMBULATORY SURGICAL CENTERS
14.5 OTHERS
15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 PHARMACIES
15.2.1 HOSPITAL
15.2.2 RETAIL
15.3 DIRECT TENDER
15.4 RETAIL SALES
15.5 OTHERS
16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GLAXOSMITHKLINE PLC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANLYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 ABBVIE INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MYLAN N. V. (A PART OF VIATRIS INC.).
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ALVOGEN
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BAYER AG
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 BEURER GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOELECTRONICS CORPORATION
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 COLOR SEVEN CO., LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 CUMBERLAND PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 LIVIA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MYOVANT SCIENCES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NOBELPHARMA CO., LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 OBSEVA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 PMS4PMS, LLC
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 SANOFI
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS
TABLE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 8 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 52 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 53 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 78 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 79 U.S. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 80 U.S. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 81 U.S. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 82 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 95 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 U.S. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 101 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 103 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 104 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 105 CANADA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 117 CANADA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 118 CANADA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 119 CANADA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 120 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 121 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 CANADA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 CANADA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 130 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 131 MEXICO MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 139 MEXICO DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 140 MEXICO SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 141 MEXICO THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 142 MEXICO HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 143 MEXICO BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 144 MEXICO DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 147 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 MEXICO ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 149 MEXICO PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 151 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 152 MEXICO PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028
FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
FIGURE 14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020
FIGURE 19 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)
FIGURE 21 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020
FIGURE 23 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)
FIGURE 24 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)
FIGURE 25 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020
FIGURE 31 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 32 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 36 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 39 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 40 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 42 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)
FIGURE 43 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.